

Business update May 2018

New stage in industrialisation
Commercial negotiations on track
Confirmation of the target of marketing authorisation filings¹

Dijon, 16 May 2018

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing and soon to market a portfolio of drugs for use in emergency situations, provides a business update in line with its financial agenda.

Patrick Alexandre, CEO of Crossject, said: *"We are proud to announce the regulatory approval of our industrial production of gas generators, a technology unique in the world that is at the heart of the ZENEO® system. Our efforts are focused on continuing the approval of the overall industrial system and on commercial negotiations for ZENEO® Sumatriptan and ZENEO® Midazolam. We have made tangible progress and are confident about achieving our goals."*

Industrialisation

The production line of the pyrotechnic gas generators of the ZENEO® system has received approval in the regulatory sense, a step prior to the approval of all production lines, and then the production of clinical batches for bioequivalence studies.

The PARC® production line has already produced a total of 55,000 glass tubes without anomalies.

¹ MA: Marketing authorisation issued by the relevant regulatory authorities.



Confirmation of the target of marketing authorisation filings

Crossject confirms its target for the filing of MA applications in the US and Europe: 2019 for ZENEO® Sumatriptan, ZENEO® Midazolam, ZENEO® Adrenaline, ZENEO® Hydrocortisone, ZENEO® Naloxone; 2020 for ZENEO® Methotrexate and ZENEO® Terbutaline.

Progress in commercial negotiations

Crossject is actively pursuing its negotiations to obtain a licensing agreement for ZENEO® Sumatriptan in the United States. Negotiations are on track for signing around mid-2018.

In addition, the tender process launched in December 2017 to find a partner to market ZENEO® Midazolam in the United States is going as planned.

Next release: 26 September 2018 (after trading): Interim 2018 results

Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Investor relations
CM-CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cmcic.fr

Press relations
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Audrey Lachat +33 (0)3 80 43 54 89
audrey.lachat@buzzetcompagnie.com

About CROSSJECT · www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, severe migraine, allergic shock, overdose and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and has notably received financing from Bpifrance.